Azitra Stock Forum

$Azitra (AZTR.US)$ Azitra Inc. has received a 'Buy' rating, bolstered by significant progress in its ATR-12 and ATR-04 programs. ATR-12, a genetically modified strain of Staphylococcus epidermidis, is being developed to treat Netherton syndrome, a severe and chronic skin disorder. The company has initiated a Phase 1b clinical trial for ATR-12, marking a crucial step in its development. Additionally, the FDA has granted Fast Track designation to ATR-04, another genetically modified s...

$Azitra (AZTR.US)$  Key updates include a $10 million follow-on offering, the dosing of the first Netherton syndrome patient with ATR-12, an IND clearance and Fast Track designation for ATR-04, and new patent approvals. Upcoming milestones in early 2025 include safety data for ATR-12 and a Phase 1/2 trial for ATR-04 targeting EGFR inhibitor rash. Financially, Azitra reported no revenue for Q3 2024, with increased R&D and G&A expenses totaling $2.9 million, and ...

$Azitra (AZTR.US)$ On November 12, 2024, Azitra, Inc. announced its third-quarter financial results, reporting a net loss of $3.2 million, up from $2.8 million last year, largely due to increased research and development expenses as it progresses with its clinical programs. The company has $5.6 million in cash, supporting its operational runway and ongoing trials. Azitra also noted key advancements, including the start of a Phase 1b trial for ATR-12 for Netherton syndrome and receivi...

$Azitra (AZTR.US)$ earnings does not matter. hope there is some release of the data related to the studies !!!!

$Azitra (AZTR.US)$ The results from Azitra's preclinical studies and ongoing clinical trials appear to be positive:
Preclinical Results: The preclinical data for ATR-12, particularly for Netherton syndrome, has shown promising outcomes. ATR-12, an engineered strain of Staphylococcus epidermidis, effectively delivered the missing LEKTI protein in models of the disorder. Additionally, it significantly reduced markers associated with inflammation and protease activity, which are ...

$Azitra (AZTR.US)$ lfg.... Bayer

$Azitra (AZTR.US)$ Keep at it 👏
Azitra to Present at BIO-Europe 2024

$Bright Minds Biosciences (DRUG.US)$ $AMTD Digital (HKD.US)$ these following tickers can move just with volume - no real walls $Wang & Lee Group (WLGS.US)$ $Azitra (AZTR.US)$

$Azitra (AZTR.US)$ has significant developments expected soon. They plan to present new data on their clinical programs, including ATR-12 (for Netherton syndrome) and ATR-04 (targeting rashes caused by EGFR inhibitors) by late 2024 and early 2025, respectively. The FDA recently granted Fast Track Designation to ATR-04, which could accelerate its development and review process.
The probability of a product reaching the market depends on the success of their clinical trials. ATR-12 is in Pha...